Article

Adapt AO outperforms conventional lens

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL.

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL, according to Ann Haustermans, Belgium.

The multicentre, prospective, intra-individual, comparative study enrolled 69 patients requiring bilateral cataract surgery. One eye of each subject received the Adapt AO and the other the spherical Akreos Adapt lens. Follow-up data was collected at one and three months and one and two years, and patients completed a questionnaire assessing their quality of vision at three months.

At one-month follow-up, the Adapt AO performed significantly better in low contrast UCVA (p=0.03) and BCVA (p=0.047). It was also found to perform better than the spherical Adapt at all spatial frequencies in photopic contrast sensitivity and at 1, 5 and 6 cpd in mesopic contrast sensitivity. At three-months follow-up, the lenses performed equally but at one year the Adapt AO performed better in high contrast UCVA and BCVA.

Dr Haustermanns concluded that the aspheric Akreos Adapt AO lens offers better optical performance than the conventional spherical Adapt IOL.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.